RT Journal Article
SR Electronic
T1 The CURE trial: Using clopidogrel in acute coronary syndromes without ST-segment elevation
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 377
OP 385
VO 69
IS 5
A1 Gregory P. Gerschutz
A1 Deepak L. Bhatt
YR 2002
UL http://www.ccjm.org/content/69/5/377.abstract
AB In a large, randomized, placebo-controlled trial in centers that use a conservative approach to acute coronary syndromes, the antiplatelet drug clopidogrel (Plavix) decreased the rate of the combined end point of cardiovascular death, nonfatal myocardial infarction, or stroke by 20% in patients presenting with acute coronary syndromes without ST-segment elevation. The benefit was at the cost of an increase in bleeding, however. This strategy may need to be tailored in centers that use a more aggressive treatment strategy of early angiography and revascularization.